Physician profile
Nicholas Ranson
NPI 1790783041
$4,499.86
in general payments reported to CMS, 2019-2025
15 companies · $668 in 2025
The $668 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $2,275 · 2021: $350 · 2022: $267 · 2024: $700 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,381.38 | 2019-2021 | |
| US Retina LLC | $666.71 | 2019-2022 | |
| Amgen INC. | $306.21 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $225.00 | 2022-2024 | Hydrus Microstent, Argos |
| Ani Pharmaceuticals, INC. | $144.50 | 2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Tarsus Pharmaceuticals, INC. | $136.23 | 2024 | Xdemvy |
| Bausch & Lomb Americas INC. | $135.25 | 2024 | Infuse, Miebo, Xiidra |
| Dompe US, INC. | $124.99 | 2024 | Oxervate |
| Abbvie INC. | $99.12 | 2025 | |
| Penumbra, INC. | $96.88 | 2025 | Benchmark |
| Sun Pharmaceutical Industries INC. | $75.01 | 2024-2025 | |
| Oyster Point Pharma, INC. | $48.45 | 2024-2025 | Tyrvaya |
| Merz Pharmaceuticals, LLC | $25.43 | 2021 | |
| Lombart Brothers, INC. | $22.59 | 2019 | |
| Allergan, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,669.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Ranson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.